Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.
Part 1 of the Phase 2 studies showed that ANVS401 was effective in treating both Alzheimer’s and Parkinson’s. The safety and efficacy results of part 2, which studied a range of doses in 40 patients with Parkinson’s, will be released this fall. Annovis plans to complete its analysis of the data over the next few months before submitting it to the FDA in hopes of beginning a Phase 3 trial early next year.